Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Herbalife yesterday and set a price target of $25.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Anthony Vendetti has given his Buy rating due to a combination of factors, including stronger-than-expected preliminary first-quarter 2026 results and improving fundamentals across key regions. He highlights that sales exceeded both company guidance and market expectations, with notable strength in India following a tax cut and solid growth in Latin America and EMEA, which together underscore the resilience of Herbalife’s global distributor network.
He also views the acquisition of Bioniq assets and the related personalized nutrition capabilities as strategically attractive, complementing earlier deals and broadening the product offering. In addition, he expects stable free cash flow generation, sees the planned refinancing of high-cost debt as a catalyst for better profitability, and believes the current valuation significantly undervalues the company relative to peers given early turnaround progress and an improving post-FTC regulatory profile.